Doctor breaks down study showing GLP-1s may lower breast cancer risk

Key Points:

• A new study published in JCO Oncology Practice suggests that GLP-1 medications may reduce the risk of developing breast cancer by about 30% in overweight or obese women aged 45 to 80.
• The study analyzed health records of over 111,000 women from the University of Pennsylvania Health System and found potential links between GLP-1s, reduced inflammation, improved insulin sensitivity, and lower breast cancer risk.
• Researchers caution the findings are observational and not definitive, emphasizing the study is hypothesis-generating and not yet practice-changing, but it adds to growing evidence on GLP-1 drugs as possible cancer prevention tools.
• Breast cancer remains the second-most common cancer and second leading cause of cancer death among U.S. women, with improved outcomes attributed to earlier screenings, better treatments, and increased awareness.
• Current guidelines recommend mammograms every two years for women aged 40 to 74 at average risk, while those at higher risk should consult their healthcare providers about screening timing.